Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

SPRY ARS Pharmaceuticals Inc

9,10

0,00 (0,00%)

17 Mai 2024 - Geschlossen

Verzögert um 15 Minuten

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

ARS Pharmaceuticals (NASDAQ:SPRY)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more ARS Pharmaceuticals Charts.

ARS Pharmaceuticals (NASDAQ:SPRY)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more ARS Pharmaceuticals Charts.

News ARS Pharmaceuticals Inc

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 17 Mai 2024 (7 Stunden vor) • Edgar (US Regulatory)

Form 8-K - Current report
Freitag 10 Mai 2024 (7 Tage vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 10 Mai 2024 (1 Woche vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 9 Mai 2024 (1 Woche vor) • Edgar (US Regulatory)

ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
Donnerstag 9 Mai 2024 (1 Woche vor) • GlobeNewswire Inc.

ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
Dienstag 30 April 2024 (2 Wochen vor) • GlobeNewswire Inc.

ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
Mittwoch 3 April 2024 (1 Monat vor) • GlobeNewswire Inc.

ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Donnerstag 21 März 2024 (2 Monate vor) • GlobeNewswire Inc.

ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day
Donnerstag 7 März 2024 (2 Monate vor) • GlobeNewswire Inc.

Form 8-K - Current report
Donnerstag 7 März 2024 (2 Monate vor) • Edgar (US Regulatory)

ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024
Mittwoch 6 März 2024 (2 Monate vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Samstag 2 März 2024 (3 Monate vor) • Edgar (US Regulatory)

Weitere ARS Pharmaceuticals Inc News-Artikel

Common Stock (CE)

Ivz Msci Wd Esg

X Trade Brokers Dom Makl...

Social Capital Hedosophi...

Copper Reef Mining

Ambrus Tax Conscious Cal...

Vontobel Financial Produ...

Wolfden Resources (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen